BSE - Delayed Quote INR
Vivanza Biosciences Limited (VIVANZA.BO)
2.2000
-0.0300
(-1.35%)
At close: 3:29:19 PM GMT+5:30
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
113,543
278,350
178,069
104,002
98,883.0490
Cost of Revenue
100,032
259,505
165,062
96,535
91,526.2450
Gross Profit
13,511
18,845
13,007
7,467
7,356.8040
Operating Expense
8,814
7,877
5,717
6,631
6,058.0350
Operating Income
4,697
10,968
7,290
836
1,298.7690
Net Non Operating Interest Income Expense
-3,700
-4,189
-4,254
-4,315
-511.2790
Pretax Income
576
6,952
7,165
3,334
1,234.8590
Tax Provision
1,479
1,479
1,181
4
481.5060
Net Income Common Stockholders
-903
5,473
5,983
3,330
753.3530
Diluted NI Available to Com Stockholders
-903
5,473
5,983
3,330
753.3530
Basic EPS
-0.15
0.01
0.15
0.08
0.02
Diluted EPS
-0.15
0.01
0.15
0.08
0.02
Basic Average Shares
40,306.2500
40,000
40,000
40,000
40,000
Diluted Average Shares
40,306.2500
40,000
40,000
40,000
40,000
Rent Expense Supplemental
--
--
125
248
50
Total Expenses
108,846
267,382
170,779
103,166
97,584.2800
Net Income from Continuing & Discontinued Operation
-903
5,473
5,983
3,330
753.3530
Normalized Income
-645.4000
5,762.7100
6,290.3429
3,697.5585
980.6689
Interest Income
--
--
--
--
4,232.4950
Interest Expense
3,641
4,130
4,186
4,056
4,675.9460
Net Interest Income
-3,700
-4,189
-4,254
-4,315
-511.2790
EBIT
4,217
11,082
11,351
7,390
5,910.8050
EBITDA
4,429
11,203
11,377
7,464
6,009.2300
Reconciled Cost of Revenue
100,032
259,505
165,062
96,535
91,526.2450
Reconciled Depreciation
212
121
26
74
98
Net Income from Continuing Operation Net Minority Interest
-903
5,473
5,983
3,330
753.3530
Total Unusual Items Excluding Goodwill
-368
-368
-368
-368
-372.6050
Total Unusual Items
-368
-368
-368
-368
-372.6050
Normalized EBITDA
4,797
11,571
11,745
7,832
6,381.8350
Tax Rate for Calcs
0.0003
0.0002
0.0002
0
0.0004
Tax Effect of Unusual Items
-110.4000
-78.2900
-60.6571
-0.4415
-145.2891
3/31/2021 - 10/23/2012
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade